Table 1.
Characteristics of the study population.
| control (N = 567) | AD (N = 150) | All (N = 717) | |
|---|---|---|---|
| Age at diagnosis or last visit (years) | |||
| Mean (SD) | 68.6 (7.17) | 73.2 (8.26) | 69.6 (7.64) |
| Sex | |||
| Men | 200 (35.3%) | 50 (33.3%) | 250 (34.9%) |
| Women | 367 (64.7%) | 100 (66.7%) | 467 (65.1%) |
| Plasma pTau181 cut-off | |||
| < 2.33 (Biomarker −) | 376 (66.3%) | 57 (38.0%) | 433 (60.4%) |
| ≥ 2.33 (Biomarker +) | 163 (28.7%) | 87 (58.0%) | 250 (34.9%) |
| Missing | 28 (4.9%) | 6 (4.0%) | 34 (4.7%) |
| APOE\varvecϵ4 allele | |||
| ϵ4 allele absent | 358 (63.1%) | 86 (57.3%) | 444 (61.9%) |
| At least 1ϵ4 allele | 20 6 (36.3%) | 64 (42.7%) | 270 (37.7%) |
| Missing | 3 (0.5%) | 0 (0%) | 3 (0.4%) |
| Plasma pTau181 | |||
| Mean (SD) | 2.13 (1.00) | 3.02 (1.67) | 2.32 (1.23) |
| Missing | 28 (4.9%) | 6 (4.0%) | 34 (4.7%) |
| Plasma NfL | |||
| Mean (SD) | 17.3 (19.2) | 26.4 (20.5) | 19.2 (19.8) |
| Missing | 28 (4.9%) | 6 (4.0%) | 34 (4.7%) |
| Plasma GFAP | |||
| Mean (SD) | 140 (95.9) | 219 (163) | 157 (118) |
| Missing | 28 (4.9%) | 6 (4.0%) | 34 (4.7%) |
| Plasma A\varvecβ42/A\varvecβ40 ratio | |||
| Mean (SD) | 0.053 (0.031) | 0.049 (0.011) | 0.053 (0.028) |
| Missing | 33 (5.8%) | 7 (4.7%) | 40 (5.6%) |